High-sensitivity troponin: A new tool for pathophysiological investigation and clinical practice

Advances in Clinical Chemistry

Volumn 49, Issue 1, 2009, Pages 1-30

  Clerico, Aldo ^a,b   Giannoni, Alberto ^a,b   Prontera, Concetta ^a   Giovannini, Stefania ^a  

^a CNR   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TROPONIN C; TROPONIN I;

BLOOD; HEART INFARCTION; HUMAN; PATHOPHYSIOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY;

HUMANS; MYOCARDIAL INFARCTION; SENSITIVITY AND SPECIFICITY; TROPONIN C; TROPONIN I;

EID: 73349131123     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(09)49001-2     Document Type: Review

References (111)

1. J.S. Alpert, K. Thygesen, E. Antman, J.P. Bassand, Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction, J. Am. Coll. Cardiol. 36 (2000) 959-969.
2. K. Thygesen, J.S. Alpert, H.D. White, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Universal definition of myocardial infarction, J. Am. Coll. Cardiol. 50 (2007) 2173-2195.
3. J. Trevelyan, E.W.A. Needham, S.C.H. Smith, R.K. Mattu, Impact of the recommendations for the redefinition of miocardial infarction on diagnosis and prognosis in an unselected United Kingdom cohort with suspected cardiac chest pain, Am. J. Cardiol. 93 (2004) 817-821.
4. M. Panteghini, The new definition of myocardial infarction and the impact of troponin determination on clinical practice, Int. J. Cardiol. 106 (2006) 298-306.
5. S. Vittorini, A. Clerico, Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice, Clin. Chem. Lab. Med. 46 (2008) 748-763.
6. F.S. Apple, R.L. Jesse, L.K. Newby, et al., National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes, Clin. Chem. 53 (2007) 547-551.
7. R.H. Christenson, S.H. Duh, F.S. Apple, et al., Standardization of cardiac troponin I assays: round robin of ten candidate reference materials, Clin. Chem. 47 (2001) 431-437.
8. M. Panteghini, F. Pagani, K.T.J. Yeo, et al., Evaluation of imprecision for cardiac troponin assays at low-range concentrations, Clin. Chem. 50 (2004) 327-332.
9. S. Takeda, A. Yamashita, K. Maeda, Y. Maéda, Structure of the core domain of human cardiac troponin in the Ca(2+)-saturated form, Nature 424 (6944) (2003) 35-41.
10. F.S. Apple, Cardiac troponin testing in renal failure and skeletal muscle disease patients, in: A.H.B. Wu (Ed.), Cardiac Markers, second ed., Homan Press, Totowa, NJ, 2003, pp. 139-147.
11. M. Panteghini, Acute coronary syndrome. Biochemical strategies in the troponin era, Chest 122 (2002) 1428-1435.
12. F.S. Apple, M.M. Murakami, The diagnostic utility of cardiac biomarkers in detecting myocardial infarction, Clin. Cornerstone 7 (Suppl. 1) (2005) S25-S30.
13. A.S. Jaffe, L. Babuin, F.S. Apple, Biomarkers in acute cardiac disease. The present and the future, J. Am. Coll. Cardiol. 48 (2006) 1-11.
14. M. Panteghini, Assay-related issues in the measurement of cardiac troponins, Clin. Chim. Acta 402 (2009) 88-93.
15. M. Panteghini, D.M. Bunk, R.H. Christenson, et al., Standardization of troponin I measurements: an update, Clin. Chem. Lab. Med. 46 (2008) 1501-1506.
16. K.M. Eggers, L. Lind, P. Venge, B. Lindahl, Will the universal definition of myocardial infarction criteria result in an overdiagnosis of myocardial infarction? Am. J. Cardiol. 103 (2009) 588-591.
17. F.S. Apple, M.A.M. Muratami, Serum and plasma cardiac troponin I 99th percentile reference values for 3 2nd generation assays, Clin. Chem. 53 (2007) 1558-1560.
18. K.M. Eggers, B. Lagerquist, P. Venge, L. Wallentin, B. Lindahl, Persistent troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts longterm mortality, Circulation 107 (2007) 1907-1914.
19. S.E. Melanson, D.A. Morrow, P. Jarolim, Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity, Am. J. Clin. Pathol. 128 (2007) 282-286.
20. D. Hermsen, F. Apple, L. Garcia-Beltràn, et al., Results from a multicenter evaluation of the 4th generation Elecsys Troponin T assay, Clin. Lab. 53 (2007) 1-9.
21. C. Prontera, A. Fortunato, S. Storti, et al., Evaluation of analytical performance of the siemens ADVIA TnI ultra immunoassay, Clin. Chem. 53 (2007) 1722-1723.
22. J. Jarausch, S. Braun, A. Dolci, et al., Evaluation of a development version of the Elecsys high sensitive troponin T assay, Clin. Chem. 54 (Suppl. 6) (2008) A91.
23. R. Beyrau, S. Braun, R. Cooray, et al., Multicentre evaluation of a high sensitive Elecsys troponin T assay, Clin. Chem. Lab. Med. 47 (2009) S128.
24. M.S. Sabatine, D.A. Morrow, J.A. de Lemos, P. Jarolim, E. Braunwald, Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35, Eur. Heart J. 30 (2009) 162-169.
25. P. Venge, S. James, L. Jansson, B. Lindahl, Clinical performance of two highly sensitive cardiac troponin I assays, Clin. Chem. 55 (2009) 109-116.
26. M. Redpath, G. Chalmers, C. Dibden, B. Morris, A. Blumsohn, Evaluation of imprecision of ADVIA Centaur® TNI-UltraTM automated immunoassay, Ann. Clin. Biochem. 45 (Suppl. 1) (2008) 57.
27. D. Van de Kerkhof, B. Peters, V. Scharnhorst, Performance of the Advia Centaur secondgeneration troponin assay TnI-Ultra compared with the first-generation cTnI assay, Ann. Clin. Biochem. 45 (2008) 316-317.
28. A. Clerico, A. Fortunato, C. Prontera, A. Ripoli, G.C. Zucchelli, M. Emdin, Distribution of plasma cardiac troponin-I values in healthy subjects: pathophysiological considerations, Clin. Chem. Lab. Med. 46 (2008) 804-808.
29. C. Prontera, A. Fortunato, S. Storti, et al., Evaluation of analytical performance of Advia TnI ultra immunoassay and comparison with Access AccuTnI method, Immuno-Analyse Biol. Spec. 23 (2008) 311-318.
30. J.C.J.M. Swaanenburg, P.J. Visser-VanBrummen, M.J.L. DeJongste, Tiebosch ATHM. The content and distribution of troponin I, troponin T, myoglobin, and alpha-hydrobytyric acid dehydrogenase in the human heart, Am. J. Clin. Pathol. 115 (2001) 770-777.
31. M. Emdin, S. Vittorini, C. Passino, A. Clerico, Old and new biomarkers of heart failure, Eur. J. Heart Fail. 11 (2009) 331-335.
32. Clinical and Laboratory Standards Institute, Approved guideline; Protocols for determination of limits of detection and limits of quantitation, (2004) CLSI document EP17-A
33. C.A. Spencer, M. Takeuchi, M. Kazarosyan, F. MacKenzie, G.J. Beckett, E. Wilkinson, Interlaboratory/intermethod diVerences in functional sensitivity of immunometric assays of thyrotropin (TSH) and impact on reliability of measurement of subnormal concentrations of TSH, Clin. Chem. 41 (1995) 367-374.
34. International vocabulary of metrology, Basic and general concepts and associated terms (VIM). Document produced by the Working Group 2 of the Joint Committee for Guides in Metrology (JCGM/WG 2), JCGM, (2008) 200.
35. A.H.B. Wu, Q.A. Lu, J. Todd, J. Moecks, F. Wians, Short- and long-term biological variation in cardiac troponin I measured with a high sensitivity assay: implications for clinical practice, Clin. Chem. 55 (2009) 52-58.
36. M. Zaninotto, M. Mion, S. Altinier, M. Forni, M. Plebani, Quality specifications for biochemical markers of myocardial injury, Clin. Chim. Acta 346 (2004) 65-72.
37. J.R. Tate, W. Ferguson, R. Bais, K. Kostner, T. Marwick, A. Carter, The determination of the 99th centile level for troponin assays in an Australian reference population, Ann. Clin. Biochem. 45 (2008) 275-288.
38. P.O. Collinson, O. Clifford-Mobley, D. Gaze, F. Boa, R. Senior, Assay imprecision and 99th-percentile reference value of a high-sensitivity cardiac troponin I assay, Clin. Chem. 55 (2009) 1433-1434.
39. F.S. Apple, A new season for cardiac troponin assays: it's time to keep a scorecard, Clin. Chem. 55 (2009) 1303-1306.
40. S. James, P. Armstrong, R. Califf, et al., Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial, Am. J. Med. 115 (2003) 178-184.
41. B. Lindahl, E. Diderholm, B. Lagerqvist, P. Venge, L. Wallentin, Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy, J. Am. Coll. Cardiol. 38 (2001) 979-986.
42. D.A. Morrow, C.P. Cannon, N. Rifai, et al., Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial, JAMA 286 (2001) 2405-2412.
43. P. Venge, B. Lagerqvist, E. Diderholm, B. Lindahl, L. Wallentin, Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease, Am. J. Cardiol. 89 (2002) 1035-1041.
44. J.R. Tale, Troponin revisited 2008: assay performance, Clin. Chem. Lab. Med. 46 (2008) 1489-1500.
45. K.M. Eggers, A.S. Jaffe, L. Lind, P. Venge, B. Lindahl, Value of cardiac troponin I cutoff concentrations below the 99th percentile for clinical decision-making, Clin. Chem. 55 (2009) 85-92.
46. A. Mingels, L. Jacobs, E. Michielsen, J. Swaanenburg, W. Wodzig, M. van Dieijen-Visser, Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays, Clin. Chem. 55 (2009) 101-108.
47. Clinical and Laboratory Standards Institute, Defining, establishing, and verifying reference intervals in the clinical laboratory; Proposed guideline, third ed., Clinical and Laboratory Standards Institute, Wayne, PA, 2008 CLSI document C28-P3.
48. P.E. Hickman, T. Badrick, S.R. Wilson, D. McGill, Reporting of cardiac troponin- problems with the 99th population centile, Clin. Chim. Acta 381 (2007) 182-183.
49. Y. Chen, R.C. Serfass, S.M. Mackey-Bojack, K.L. Kelly, J.L. Titus, F.S. Apple, Cardiac troponin T alterations in myocardium and serum of rats after stressful, prolonged intense exercise, J. Appl. Physiol. 88 (2000) 1749-1755.
50. P. Anversa, A. Leri, J. Kajstura, B. Nadal-Ginard, Myocyte growth and cardiac repair, J. Mol. Cell. Cardiol. 34 (2002) 91-105.
51. R.K. Illango, Utilizing NT-proBNP in the selection of risks for life insurance, J. Insur. Med. 39 (2007) 182-191.
52. J.M. Ribera-Casado, Ageing and the cardiovascular system, Z. Gerontol. Geriatr. 32 (1999) 412-419.
53. K.G. Pugh, J.Y. Wei, Clinical implications of physiological changes in the aging heart, Drugs Aging 18 (2001) 263-276.
54. K.M. Eggers, L. Lind, H. Ahlstrom, et al., Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects, Eur. Heart J. 29 (2008) 2252-2258.
55. D.A. Morrow, E.M. Antman, Evaluation of high-sensitivity assays for cardiac troponin, Clin. Chem. 55 (2009) 5-9.
56. S.E. Melanson, M.J. Conrad, N. Mosammaparast, P. Jarolim, Implementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results, Clin. Chim. Acta 395 (2008) 57-61.
57. P.A. Kavsak, A.R. MacRae, M.J. Yerna, A.S. Jaffe, Analytical and clinical utility of a next-generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury, Clin. Chem. 55 (2009) 573-577.
58. A.H. Wu, Interpretation of high sensitivity cardiac troponin I results: reference to biological variability in patients who present to the emergency room with chest pain: case report series, Clin. Chim. Acta 401 (2009) 170-174.
59. H.D. White, Will new higher-precision troponins lead to clarify or confusion? Curr. Opin. Cradiol. 23 (2008) 292-295.
60. A.H. Wu, A.S. Jaffe, F.S. Apple, et al., NACB Writing Group; Cannon CP, Storrow AB; NACB Committee, National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure, Clin. Chem. 53 (2007) 2086-2096.
61. A.H. Wu, A.S. Jaffe, The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing, Am. Heart J. 155 (2008) 208-214.
62. S.A. Hunt, D.W. Baker, M.H. Chin, et al., ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure), J. Am. Coll. Cardiol. 38 (2001) 2101-2113.
63. S.A. Hunt, American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure), ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure), J. Am. Coll. Cardiol. 46 (2005) e1-e82.
64. S.A. Hunt, W.T. Abraham, M.H. Chin, American College of Cardiology Foundation; American Heart Association, 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation, J. Am. Coll. Cardiol. 53 (2009) e1-e90.
65. K. Swedberg, J. Cleland, H. Dargie, et al., Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology, Eur. Heart J. 26 (2005) 1115-1140.
66. R. Latini, S. Masson, I.S. Anand, et al., Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure, Circulation 116 (2007) 1242-1249.
67. T.W. Wallace, S.M. Abdullah, M.H. Drazner, et al., Prevalence and determinants of troponin T elevation in the general population, Circulation 113 (2006) 1958-1965.
68. D. Cardinale, M.T. Sandri, A. Colombo, et al., Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy, Circulation 109 (2004) 2749-2754.
69. D. Cardinale, A. Colombo, M.T. Sandri, et al., Prevention of high-dose chemotherapyinduced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition, Circulation 114 (2006) 2474-2481.
70. M. Maeder, T. Fehr, H. Rickli, P. Ammann, Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides, Chest 129 (2006) 1349-1366.
71. A. Dispenzieri, M.A. Gertz, R.A. Kyle, et al., Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis, J. Clin. Oncol. 22 (2004) 3751-3757.
72. G. Merlini, G. Palladini, Amyloidosis is a cure possible? Ann. Oncol. 19 (Suppl. 4) (2008) iv63-iv66.
73. C. Passino, R. Poletti, M. Fontana, et al., Clinical relevance of non-cardiac determinants of natriuretic peptide levels, Clin. Chem. Lab. Med. 46 (2008) 1515-1523.
74. T. Pham, L. Gossec, A. Constantin, et al., Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion, Joint Bone Spine 73 (2006) 379-387.
75. A. Kahan, Y. Allanore, Primary myocardial involvement in systemic sclerosis, Rheumatology 45 (Suppl. 4) (2006) 14-17.
76. N. Assous, E. Touzé, C. Meune, A. Kahan, Y. Allanore, Cardiovascular disease in rheumatoid arthritis: single-center hospital-based cohort study in France, Joint Bone Spine 74 (2007) 66-72.
77. A.Y. Wang, K.N. Lai, Use of cardiac biomarkers in end-stage renal disease, J. Am. Soc. Nephrol. 19 (2008) 1643-1652.
78. C. Sommerer, E. Giannitsis, V. Schwenger, M. Zeier, Cardiac biomarkers in haemodialysis patients: the prognostic value of amino-terminal pro-B-type natriuretic peptide and cardiac troponin T, Nephron Clin. Pract. 107 (2007) c77-c81.
79. L.H. Jacobs, J. van de Kerkhof, A.M. Mingels, et al., Haemodialysis patients longitudinally assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and cardiac troponin I assays, Ann. Clin. Biochem. 46 (2009) 283-290.
80. D.A. Marshall, B.J. O'Brien, Economic evaluation of diagnostic tests, in: P.C. Price, R.H. Christensen (Eds.), Evidence-based laboratory medicine-from principles to outcomes, AACC Press, Washington, DC, 2003, pp. 159-186.
81. D.A. Morrow, C.P. Cannon, R.L. Jesse, et al., National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes, Clin. Chem. 53 (2007) 552-574.
82. O. Bergmann, R.D. Bhardwaj, S. Bernard, et al., Evidence for cardiomyocyte renewal in humans, Science 324 (5923) (2009) 98-102.
83. M.H. Hessel, D.E. Atsma, E.J. van der Valk, W.H. Bax, M.J. Schalij, A. van der Laarse, Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation, Pflugers Arch. 455 (2008) 979-986.
84. M.H. Hessel, E.C. Michielsen, D.E. Atsma, et al., Release kinetics of intact and degraded troponin I and T after irreversible cell damage, Exp. Mol. Pathol. 85 (2008) 90-92.
85. W. Wang, C.J. Schulze, W.L. Suarez-Pinzon, J.R. Dyck, G. Sawicki, R. Schulz, Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury, Circulation 106 (2002) 1543-1549.
86. J.Y. Shyy, S. Chien, Role of integrins in cellular responses to mechanical stress and adhesion, Curr. Opin. Cell Biol. 9 (1997) 707-713.
87. M.S. Clarke, R.W. Caldwell, H. Chiao, K. Miyake, P.L. McNeil, Contraction-induced cell wounding and release of fibroblast growth factor in heart, Circ. Res. 76 (1995) 927-934.
88. D. Kaye, D. Pimental, S. Prasad, et al., Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro, J. Clin. Invest. 97 (1996) 281-291.
89. P.L. McNeil, R. Khakee, Disruptions of muscle fiber plasma membranes. Role in exerciseinduced damage, Am. J. Pathol. 140 (1992) 1097-1109. 28 CLERICO ET AL.
90. E. Page, J. Upshaw-Earley, G. Goings, Permeability of rat atrial endocardium, epicardium, and myocardium to large molecules. Stretch-dependent effects, Circ. Res. 71 (1992) 159-173.
91. R.E. Shave, E. Dawson, G. Whyte, et al., Evidence of exercise-induced cardiac dysfunction and elevated cTnT in separate cohorts competing in an ultra-endurance mountain marathon race, Int. J. Sports Med. 23 (2002) 489-494.
92. M. Herrmann, J. Scharhag, M. Miclea, A. Urhausen, W. Herrmann, W. Kindermann, Post-race kinetics of cardiac troponin T and I and N-terminal pro-brain natriuretic peptide in marathon runners, Clin. Chem. 49 (2003) 831-834.
93. H.J. Roth, R.M. Leithäuser, H. Doppelmayr, et al., Cardiospecificity of the 3rd generation cardiac troponin T assay during and after a 216 km ultra-endurance marathon run in Death Valley, Clin. Res. Cardiol. 96 (2007) 359-364.
94. E.B. Fortescue, A.Y. Shin, D.S. Greenes, et al., Cardiac troponin increases among runners in the Boston Marathon, Ann. Emerg. Med. 49 (2007) 137-143.
95. N. Middleton, K. George, G. Whyte, D. Gaze, P. Collinson, R. Shave, Cardiac troponin release is stimulated by endurance exercise in healthy humans, J. Am. Coll. Cardiol. 52 (2008) 1813-1814.
96. K.M. Hubble, D.M. Fatovich, J.M. Grasko, S.D. Vasikaran, Cardiac troponin increases among marathon runners in the Perth Marathon: the Troponin in Marathons (TRIM) study, Med. J. Aust. 190 (2009) 91-93.
97. N. Mousavi, A. Czarnecki, K. Kumar, et al., Relation of biomarkers and cardiac magnetic resonance imaging after marathon running, Am. J. Cardiol. 103 (2009) 1467-1472.
98. D.S. Jassal, D. Moffat, J. Krahn, et al., Cardiac injury markers in non-elite marathon runners, Int. J. Sports Med. 30 (2009) 75-79.
99. S. Vasan, Biomarkers of cardiovascular disease: molecular basis and practical considerations, Circulation 113 (2006) 2335-2362.
100. A. Clerico, S. Vittorini, C. Passino, M. Emdin, New biomarkers of heart failure, Crit. Rev. Clin. Lab. Sci. 46 (2009) 107-128.
101. A. Clerico, F.A. Recchia, C. Passino, M. Emdin, Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications, Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H17-H29.
102. A. Clerico, M. Fontana, S. Vittorini, M. Emdin, The search for a pathophysiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality: proposal for a working hypothesis, Clin. Chim. Acta 405 (2009) 1-7.
103. A. De Bold, Determinants of brain natriuretic peptide gene expression and secretion in acute cardiac allograft rejection, Curr. Opin. Cardiol. 22 (2007) 146-150.
104. S. Potluri, H.O. Ventura, M. Mulumudi, M.R. Mehra, Cardiac troponin levels in heart failure, Cardiol. Rev. 12 (2004) 21-25.
105. S.D. Wiviott, J.A. de Lemos, D.A. Morrow, Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes, Clin. Chim. Acta 346 (2004) 119-128.
106. P. Venge, J. Arnlöv, B. Zethelius, Seemingly healthy 71-year-old men with minor elevations of cardiac troponin I and at risk of premature death in CVD have elevated levels of NT-proBNP: report from the ULSAM study, Scand. Clin. Lab. Invest. 69 (2009) 418-424.
107. J.C. Lega, Y. Lacasse, L. Lakhal, S. Provencher, Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis, Thorax 64 (2009) 868-875.
108. A. Clerico, M. Emdin, Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review, Clin. Chem. 50 (2004) 33-50.
109. M. Emdin, C. Passino, C. Prontera, et al., Comparison of brain natriuretic peptide (BNP) and amino-terminal proBNP for early diagnosis of heart failure, Clin. Chem. 53 (2007) 1264-1272.
110. J. Sundström, E. Ingelsson, L. Berglund, et al., Cardiac troponin-I and risk of heart failure: a community-based cohort study, Eur. Heart J. 30 (2009) 773-781.
111. G.C. Fonarow, T.B. Horwich, Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure, Rev. Cardiovasc. Med. 4 (Suppl. 4) (2003) S20-S28.